Effects of challenge dose on the clinical and immune responses of cattle vaccinated with reduced doses of Brucella abortus strain 19

Fifty-seven pregnant beef heifers that were unvaccinated or previously vaccinated with Brucella abortus S19, at a dose of either 10⁹ or 10¹⁰ colony-forming units (CFU), were challenge-exposed intraconjunctivally with virulent B. abortus S2308 at a dose of 9.4 × 10⁶ CFU (Experiment 1) or 5.2 × 10⁷ CFU (Experiment 2). In Experiment 1, S19 afforded significant protection (P < 0.01) against challenge exposure in that 8 of 9 unvaccinated heifers, 1 of 11 vaccinated with 10⁹ CFU, and 3 of 10 vaccinated with 10¹⁰ CFU aborted or delivered weak, non-viable calves. In Experiment 2, vaccination did not afford significant protection (P> 0.05) in that 9 of 9 unvaccinated heifers, 8 of 10 vaccinated with 10⁹ CFU, and 8 of 8 vaccinated with 10¹⁰ CFU aborted. Serologic responses to B. abortus were determined by three standard tests, as well as a quantitative fluorometric immunoassay (FIAX) and an enzyme-linked immunosorbent assay. In Experiment 1, the early serologic response, 0–8 weeks after challenge, appeared greater for controls than for vaccinates, but in Experiment 2, the early response, 0–6 weeks after challenge exposure, appeared greater for vaccinates than for controls. The lymphocyte blast transformation assay, using heat-killed B. abortus as an antigen, was performed sequentially after challenge exposure. In general, mean responses were significantly higher (P < 0.05) for vaccinated than for non-vaccinated heifers. For individual heifers, an association could not be established between the lymphocyte blast transformation assay and the clinical response to challenge exposure.